Skip to main content
. Author manuscript; available in PMC: 2013 Sep 4.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2012 Sep 4;5(5):615–621. doi: 10.1161/CIRCOUTCOMES.112.967299

TABLE 1.

NATIONAL TRENDS IN TREATMENT WITH WARFARIN AND DABIGATRATION BY AGE AND OVERALL, 2007–2011.

2007 2008 2009 2010 2011
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Warfarin visits, %
     Less than 65 years of age 31 25 27 26 30 27 26 26 32 24 26 27 26 27 33 26 29 33 26 31
     65 to 74 years 23 28 28 27 27 25 31 26 25 30 27 26 30 25 26 23 22 24 32 22
     75 to 84 years 28 30 33 32 28 32 32 34 29 31 31 29 30 33 23 33 31 30 27 28
     85 years and older 14 13 10 13 10 13 10 12 11 12 14 15 13 12 14 13 15 9 12 14
     Unknown age 4 4 2 2 5 3 1 2 3 3 2 3 1 3 4 5 3 4 3 5
Total warfarin visits, N
(thousands)		 2123 207
8		 176
0		 208
7		 195
1		 219
8		 200
2		 216
6		 178
9		 201
3		 184
8		 172
8		 177
1		 183
8		 187
3		 189
9		 172
8		 158
6		 163
8		 155
6
Dabigatran visits, %
     Less than 65 years of age - - - - - - - - - - - - - - - 8 16 36 23 13
     65 to 74 years - - - - - - - - - - - - - - - 45 23 28 41 37
     75 to 84 years - - - - - - - - - - - - - - - 25 49 30 30 37
     85 years and older - - - - - - - - - - - - - - - 22 8 3 3 11
     Unknown age - - - - - - - - - - - - - - - 0 4 3 3 2
Total dabigatran visits, N (thousands) - - - - - - - - - - - - - - - 62 143 191 231 363
Dabigatran % market share - - - - - - - - - - - - - - - 3 8 11 12 19

Source: IMS Health National Disease and Therapeutic Index, 2007–2011